Performance vs S&P 500

03
Tracked Q1 2025–Q2 2026 +32.5%
S&P 500 total return (same window) +37.0%
Excess return -4.5%

Annualized: +25.2% · S&P 500: +28.7%

Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.

Priceable coverage: 97.4% · Options excluded: 7.3%

Sector breakdown

04
Healthcare 82.7%
Other/Unmapped 17.3%

Full portfolio 19 positions

05
Type Streak 8Q trend
Unknown issuer (CUSIP: 46090E953) $36,820,000 17.29% 50,000 Put option Up ×1
ADMA ADMA Biologics Inc - Common Stock $27,307,477 12.82% 3,262,542 $-1,592,476 Up ×4
PALI Palisade Bio, Inc. - Common Stock $23,855,856 11.20% 11,414,285 $3,880,857
NRXP NRX Pharmaceuticals, Inc. - Common Stock $16,735,327 7.86% 4,091,767 $10,345,327 Up ×1
SNSE Sensei Biotherapeutics, Inc. - Common Stock $15,254,225 7.16% 610,169 Up ×1
TSHA Taysha Gene Therapies, Inc. - Common Stock $12,261,786 5.76% 1,800,556 $4,213,301
PRAX Praxis Precision Medicines, Inc. - Common Stock $11,127,415 5.22% 33,237 $418,786
CLLS Cellectis S.A. - American Depositary Shares $9,844,503 4.62% 3,281,501 $-557,855
ZLAB Zai Lab Limited - American Depositary Shares $8,562,274 4.02% 450,646 $85,623
GPCR Structure Therapeutics Inc. - American Depositary Shares $7,513,800 3.53% 140,000 $1,368,300 Up ×2
ORKA Oruka Therapeutics, Inc. - Common Stock $7,137,750 3.35% 75,000 $3,459,000
IOVA Iovance Biotherapeutics, Inc. - Common Stock $6,240,000 2.93% 1,500,000 $975,000
SYRE Spyre Therapeutics, Inc. - Common Stock $6,214,600 2.92% 70,000 $1,170,600 Down ×1
AURA Aura Biosciences, Inc. - Common Stock $5,426,125 2.55% 764,243 $1,428,342 Up ×2
ASMB Assembly Biosciences, Inc. - Common Stock $4,828,401 2.27% 175,706 $-47,441
DRUG Bright Minds Biosciences Inc. - common stock $4,738,500 2.22% 67,500 $-186,975
RARE Ultragenyx Pharmaceutical Inc. - Common Stock $4,507,650 2.12% 135,000 $1,679,400
SGHT Sight Sciences, Inc. - Common Stock $3,656,900 1.72% 970,000 $0
FHTX Foghorn Therapeutics Inc. - Common Stock $976,000 0.46% 200,000 $488,440 Up ×1

Conviction holdings

08

Positions increased for 3+ consecutive quarters.

Share counts are as reported in 13F filings (not split-adjusted)

SecurityValue% of portfolioStreak
ADMA $27,307,477 12.82% up ×4

Biggest new bets

09

New positions opened this quarter, largest first.

SecurityValueShares% of portfolio
Unknown issuer (CUSIP: 46090E953) $36,820,000 50,000 17.29%
SNSE $15,254,225 610,169 7.16%

Top movers (QoQ)

10
SecurityActionShares ΔValue Δ
NRXP Bought more +1.1M +$10.3M
TSHA Price move only +0 +$4.2M
PALI Price move only +0 +$3.9M
ORKA Price move only +0 +$3.5M
RARE Price move only +0 +$1.7M
ADMA Bought more +55K -$1.6M
AURA Bought more +167K +$1.4M
GPCR Bought more +12K +$1.4M
SYRE Trimmed -30K +$1.2M
IOVA Price move only +0 +$975K

Exited positions

11

Includes corporate events (mergers, delistings) — not all exits are sells

Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.

SecurityQuarterShares beforeValue beforePrice since exit
LLY Dec. 31, 2025 22,500 $17,167,500 6.3%
NVDA Dec. 31, 2025 75,000 $13,993,500 25.4%
AKRO Dec. 31, 2025 232,446 $11,036,536 No longer tracked
NRXPW Dec. 31, 2025 3,000,000 $4,455,000 No longer tracked
BNTX June 30, 2025 15,000 $1,365,900 -9.0%
ETNB June 30, 2025 95,623 $695,179 No longer tracked
APGE June 30, 2026 7,500 $631,275 No longer tracked
SLNO June 30, 2026 7,500 $251,100 No longer tracked
REPL June 30, 2026 26,000 $198,900 18.1%
GAME Dec. 31, 2025 250,000 $169,700 0.0%
INSM Dec. 31, 2025 158 $22,754 -36.2%